-
EP3328834
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3328834
| EP3328834 - QUINOLINONE OR QUINAZOLINONE COMPRISING ANTIBIOFILM COMPOSITIONS, COMPOUNDS AND METHODS AND USES RELATING THERETO [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 26.06.2020 Database last updated on 28.03.2026 | |
| Former | Examination is in progress Status updated on 17.06.2019 | ||
| Former | Request for examination was made Status updated on 04.05.2018 | ||
| Former | The international publication has been made Status updated on 11.02.2017 | Most recent event Tooltip | 26.06.2020 | Application deemed to be withdrawn | published on 29.07.2020 [2020/31] | Applicant(s) | For all designated states University College Cork, National University Of Ireland Western Road Cork / IE | [2018/23] | Inventor(s) | 01 /
O'GARA, Fergal Biomerit Reseach Centre University College Cork Western Road Cork / IE | 02 /
REEN, Jerry F. Biomerit Reseach Centre University College Cork Western Road Cork / IE | 03 /
MCGLACKEN, Gerard Patrick Department of Chemistry University College Cork Western Road Cork / IE | [2018/23] | Representative(s) | Appleyard Lees IP LLP G Mill Dean Clough Industrial Park Halifax HX3 5AH / GB | [N/P] |
| Former [2018/23] | Appleyard Lees IP LLP 15 Clare Road Halifax HX1 2HY / GB | Application number, filing date | 16745471.9 | 01.08.2016 | [2018/23] | WO2016EP68355 | Priority number, date | GB20150013614 | 31.07.2015 Original published format: GB 201513614 | [2018/23] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2017021382 | Date: | 09.02.2017 | Language: | EN | [2017/06] | Type: | A1 Application with search report | No.: | EP3328834 | Date: | 06.06.2018 | Language: | EN | The application published by WIPO in one of the EPO official languages on 09.02.2017 takes the place of the publication of the European patent application. | [2018/23] | Search report(s) | International search report - published on: | EP | 09.02.2017 | Classification | IPC: | C07D215/233, C07D215/38, C07D239/91, A61K31/47, A61P31/00 | [2018/23] | CPC: |
C07D215/233 (EP,US);
A61P31/00 (EP,US);
C07C215/38 (US);
C07D215/38 (EP,US);
C07D239/91 (EP,US)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2018/23] | Title | German: | CHINOLINON ODER CHINAZOLINON MIT ANTIBIOFILMZUSAMMENSETZUNGEN, VERBINDUNGEN UND VERFAHREN UND VERWENDUNGEN IM ZUSAMMENHANG DAMIT | [2018/23] | English: | QUINOLINONE OR QUINAZOLINONE COMPRISING ANTIBIOFILM COMPOSITIONS, COMPOUNDS AND METHODS AND USES RELATING THERETO | [2018/23] | French: | COMPOSITIONS D'ANTIBIOFILM COMPRENANT UNE QUINOLÉINONE OU UNE QUINAZOLINONE, COMPOSÉS ET PROCÉDÉS ET UTILISATIONS RELATIVES À CES DERNIERS | [2018/23] | Entry into regional phase | 11.12.2017 | National basic fee paid | 11.12.2017 | Designation fee(s) paid | 11.12.2017 | Examination fee paid | Examination procedure | 11.12.2017 | Examination requested [2018/23] | 11.12.2017 | Date on which the examining division has become responsible | 02.10.2018 | Amendment by applicant (claims and/or description) | 21.06.2019 | Despatch of a communication from the examining division (Time limit: M06) | 03.01.2020 | Application deemed to be withdrawn, date of legal effect [2020/31] | 28.01.2020 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2020/31] | Divisional application(s) | EP19216185.9 / EP3653610 | Fees paid | Renewal fee | 23.08.2018 | Renewal fee patent year 03 | Penalty fee | Additional fee for renewal fee | 31.08.2019 | 04 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [XI] CENBIN LU ET AL: "Discovery of Antagonists of PqsR, a Key Player in 2-Alkyl-4-quinolone-Dependentin", CHEMISTRY AND BIOLOGY, CURRENT BIOLOGY, LONDON, GB, vol. 19, no. 3, 13 January 2012 (2012-01-13), pages 381 - 390, XP028475184, ISSN: 1074-5521, [retrieved on 20120127], DOI: 10.1016/J.CHEMBIOL.2012.01.015 [X] 1,2,7-10 * see the whole document, especially antagonisitc compound 20, compounds 1 to 3, 5, 6, 8 to 18 and 20 according to table 1 being no antagonists and paragraph "Significance" on p. 387 * [I] 1-10 DOI: http://dx.doi.org/10.1016/j.chembiol.2012.01.015 | [XI] CENBIN LU ET AL: "Supplemental Information Discovery of Antagonists of PqsR, a Key Player in 2-Alkyl-4-quinolone-Dependent Quorum Sensing in Pseudomonas aeruginosa Table S1, related to Table 1. Agonistic and Antagonistic Activities of PQS Analogues Table S2, related to Table 1. Determination of Water Solubility Table", CHEMISTRY & BIOLOGY, 23 March 2012 (2012-03-23), XP055300791, Retrieved from the Internet | [XI] CENBIN LU ET AL: "Optimization of anti-virulence PqsR antagonists regarding aqueous solubility and biological properties resulting in new insights in structure-activity relationships", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY., vol. 79, 1 May 2014 (2014-05-01), FR, pages 173 - 183, XP055300362, ISSN: 0223-5234, DOI: 10.1016/j.ejmech.2014.04.016 [X] 1,2,7-10 * see antagonistic compounds 2, 8 and 16 in scheme 1 and table 1 *[I] 1-10 DOI: http://dx.doi.org/10.1016/j.ejmech.2014.04.016 | [XI] CENBIN LU ET AL: "Overcoming the Unexpected Functional Inversion of a PqsR Antagonist in Pseudomonas aeruginosa : An In Vivo Potent Antivirulence Agent Targeting pqs Quorum Sensing", ANGEWANDTE CHEMIE INTERNATIONAL EDITION, vol. 53, no. 4, 11 December 2013 (2013-12-11), pages 1109 - 1112, XP055125082, ISSN: 1433-7851, DOI: 10.1002/anie.201307547 [X] 1,2,7-10 * see compounds 1 and 3 and table 1 on p. 1128 *[I] 1-10 DOI: http://dx.doi.org/10.1002/anie.201307547 | [XI] F. JERRY REEN ET AL: "A structure activity-relationship study of the bacterial signal molecule HHQ reveals swarming motility inhibition in Bacillus atrophaeus", ORGANIC & BIOMOLECULAR CHEMISTRY, vol. 13, no. 19, 1 January 2015 (2015-01-01), GB, pages 5537 - 5541, XP055299977, ISSN: 1477-0520, DOI: 10.1039/C5OB00315F [X] 1-3,5,7-10 * see compounds 7 and 10 in table 1 and p. 5539, right column. *[I] 1-10 DOI: http://dx.doi.org/10.1039/C5OB00315F | [I] F. JERRY REEN ET AL: "Structure-function analysis of the C-3 position in analogues of microbial behavioural modulators HHQ and PQS", ORGANIC & BIOMOLECULAR CHEMISTRY, vol. 10, no. 44, 1 January 2012 (2012-01-01), GB, pages 8903, XP055299557, ISSN: 1477-0520, DOI: 10.1039/c2ob26823j [I] 1-10 * see p. 8906, right column: inablity of of compound 10 to affect biofilm formation in C. albicans and compounds 8 to 11 lacking any cyctotoxicity * DOI: http://dx.doi.org/10.1039/c2ob26823j | [I] ARAVINDAN ILANGOVAN ET AL: "Structural Basis for Native Agonist and Synthetic Inhibitor Recognition by the Pseudomonas aeruginosa Quorum Sensing Regulator PqsR (MvfR)", PLOS PATHOGENS, vol. 9, no. 7, 25 July 2013 (2013-07-25), pages e1003508, XP055303660, DOI: 10.1371/journal.ppat.1003508 [I] 1-10 * see figure 2, all compounds being agonists of PqsR in P. aeruginosa * DOI: http://dx.doi.org/10.1371/journal.ppat.1003508 | [I] F. JERRY REEN ET AL: "The Pseudomonas quinolone signal (PQS), and its precursor HHQ, modulate interspecies and interkingdom behaviour", FEMS MICROBIOLOGY ECOLOGY., vol. 77, no. 2, 26 May 2011 (2011-05-26), NL, pages 413 - 428, XP055301011, ISSN: 0168-6496, DOI: 10.1111/j.1574-6941.2011.01121.x [I] 1-10 * see abstract p. 419:HHQ interfers with biofilm formation in C. albicans * DOI: http://dx.doi.org/10.1111/j.1574-6941.2011.01121.x |